title: Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
abstract: BACKGROUND
  Unsatisfactory treatment results of acute myeloblastic leukaemia inspire the search for new drugs, characterised by higher efficiency and lower toxicity. The aim of the study was the assessment of the efficiency and side effects associated with the implementation of IDA-FLAG protocol.
  
  
  METHODS
  The assessment of treatment results and undesirable effects was based on the material of 4 children with the relapse of acute myeloblastic leukaemia, after a total of 6 IDA-FLAG protocols.
  
  
  RESULTS
  Complete remission was obtained in 2 (50%) children, with mean remission time of 13.5 months. One of the children underwent the transplantation of haematopoietic cells from unrelated donor. The main side effect observed was bone marrow aplasia. Leucopenia, granulocytopenia, thrombocytopenia and anaemia persisted for approx. 20 days. Apart from haematological symptoms, the following were also observed: the symptoms of intolerance after ARA-C, aspergillosis of paranasal sinuses and lungs and severe coagulation disorders.
  
  
  CONCLUSIONS
  IDA-FLAG protocol may be recommended for use in children with AML relapse and the undesirable effects observed are acceptable.
authors.affiliation: Department of Paediatric Oncology, Medical Academy, Białystok, Poland. viodek@amb.ac.bialystok.pl
authors.forename: W
authors.initials: W
authors.lastname: Łuczyński
authors.forename: K
authors.initials: K
authors.lastname: Muszyńska-Rosłan
authors.forename: M
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: M
authors.initials: M
authors.lastname: Kuźmicz
authors.forename: A
authors.initials: A
authors.lastname: Iwaszkiewicz-Pawłowska
authors.forename: J
authors.initials: J
authors.lastname: Kaliszewski
mesh_terms: D000293:Adolescent; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D011994:Recombinant Proteins; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014740:Vidarabine; D000069585:Filgrastim; D015255:Idarubicin